Journal of International Oncology››2016,Vol. 43››Issue (2): 119-.
Previous ArticlesNext Articles
WANG Xiao, GAO Yong, LI Yan-Dong
Online:
2016-02-08Published:
2015-12-28WANG Xiao, GAO Yong, LI Yan-Dong. The correlation between nucleolin and biological behavior of tumor[J]. Journal of International Oncology, 2016, 43(2): 119-.
[1] Durut N, SáezVásquez J. Nucleolin: dual roles in rDNA chromatin transcription[J]. Gene, 2015, 556(1): 712. DOI:10.1016/j.gene.2014.09.023. [2] Abdelmohsen K, Gorospe M. RNAbinding protein nucleolin in disease[J]. RNA Biol, 2012, 9(6): 799808. DOI:10.4161/rna.19718. [3] Berger CM, Gaume X, Bouvet P. The roles of nucleolin subcellular localization in cancer[J]. Biochimie, 2015, 113: 7885. DOI:10.1016/j.biochi.2015.03.023. [4] Guo X, Xiong L, Yu L, et al. Increased level of nucleolin confers to aggressive tumor progression and poor prognosis in patients with hepatocellular carcinoma after hepatectomy[J]. Diagn Pathol, 2014, 9: 175. DOI:10.1186/s130000140175y. [5] Qiu W, Zhou F, Zhang Q, et al. Overexpression of nucleolin and different expression sites both related to the prognosis of gastric cancer[J]. APMIS, 2013, 121(10): 919925. DOI:10.1111/apm.12131. [6] Koutsioumpa M, Polytarchou C, Courty J, et al. Interplay between αvβ3 integrin and nucleolin regulates human endothelial and glioma cell migration[J]. J Biol Chem, 2013, 288(1): 343354. DOI:10.1074/jbc.M112.387076. [7] Fujiki H, Watanabe T, Suganuma M. Cellsurface nucleolin acts as a central mediator for carcinogenic, anticarcinogenic, and diseaserelated ligands[J]. J Cancer Res Clin Oncol, 2014, 140(5): 689699. DOI:10.1007/s0043201415875. [8] Qi J, Li H, Liu N, et al. The implications and mechanisms of the extranuclear nucleolin in the esophageal squamous cell carcinomas[J]. Med Oncol, 2015, 32(3): 45. DOI:10.1007/s1203201504843. [9] Xiao S, Caglar E, Maldonado P, et al. Induced expression of nucleolin phosphorylationdeficient mutant confers dominantnegative effect on cell proliferation[J]. PLoS One, 2014, 9(10): e109858. DOI:10.1371/journal.pone.0109858. [10] Wu DM, Zhang P, Liu RY, et al. Phosphorylation and changes in the distribution of nucleolin promote tumor metastasis via the PI3K/Akt pathway in colorectal carcinoma[J]. FEBS Lett, 2014, 588(10): 19211929. DOI:10.1016/j.febslet.2014.03.047. [11] Wang W, Luo J, Xiang F, et al. Nucleolin downregulation is involved in ADPinduced cell cycle arrest in S phase and cell apoptosis in vascular endothelial cells[J]. PLoS One, 2014, 9(10): e110101. DOI:10.1371/journal.pone.0110101. [12] Srivastava A, Srivastava S, Bansal C, et al. Diagnostic importance of AgNOR pleomorphism in cervical carcinogenesis[J]. Ecancermedicalscience, 2013, 7: 287. DOI:10.3332/ecancer.2013.287. [13] Malik MT, O′toole MG, Casson LK, et al. AS1411conjugated Gold nanospheres and their potential for breast cancer therapy[J]. Oncotarget, 2015, 6(26): 2227022281. [14] Liao ZX, Chuang EY, Lin CC, et al. An AS1411 aptamerconjugated liposomal system containing a bubblegenerating agent for tumorspecific chemotherapy that overcomes multidrug resistance[J]. J Control Release, 2015, 208: 4251. DOI:10.1016/j.jconrel.2015.01.032. [15] Wang WH, Childress MO, Geahlen RL. Syk interacts with and phosphorylates nucleolin to stabilize Bclx(L) mRNA and promote cell survival[J]. Mol Cell Biol, 2014, 34(20): 37883799. DOI:10.1128/MCB.0093714. [16] Wise JF, Berkova Z, Mathur R, et al. Nucleolin inhibits Fas ligand binding and suppresses Fasmediated apoptosis in vivo via a surface nucleolinFas complex[J]. Blood, 2013, 121(23): 47294739. DOI:10.1182/blood201212471094. [17] Cheng DD, Zhao HG, Yang YS, et al. GSK3β negatively regulates HIF1α mRNA stability via nucleolin in the MG63 osteosarcoma cell line[J]. Biochem Biophys Res Commun, 2014, 443(2): 598603. DOI:10.1016/j.bbrc.2013.12.020. [18] Sletten T, Kostas M, Bober J, et al. Nucleolin regulates phosphorylation and nuclear export of fibroblast growth factor 1 (FGF1)[J]. PLoS One, 2014, 9(3): e90687. DOI:10.1371/journal.pone.0090687. [19] Hsu TI, Lin SC, Lu PS, et al. MMP7mediated cleavage of nucleolin at Asp255 induces MMP9 expression to promote tumor malignancy[J]. Oncogene, 2015, 34(7): 826837. DOI:10.1038/onc.2014.22. [20] Subramanian N, Kanwar JR, Akilandeswari B, et al. Chimeric nucleolin aptamer with survivin DNAzyme for cancer cell targeted delivery[J]. Chem Commun (Camb), 2015, 51(32): 69406943. DOI:10.1039/c5cc00939a. [21] Lee JW, Kim HJ, Heo K. Therapeutic aptamers: developmental potential as anticancer drugs[J]. BMB Rep, 2015, 48(4): 234237. [22] Qiu W, Wang G, Sun X, et al. The involvement of cell surface nucleolin in the initiation of CCR6 signaling in human hepatocellular carcinoma[J]. Med Oncol, 2015, 32(3): 75. DOI:10.1007/s1203201505301. [23] Goldstein M, Derheimer FA, TaitMulder J, et al. Nucleolin mediates nucleosome disruption critical for DNA doublestrand break repair[J]. Proc Natl Acad Sci USA, 2013, 110(42): 1687416879. DOI:10.1073/pnas.1306160110. [24] Koutsioumpa M, Papadimitriou E. Cell surface nucleolin as a target for anticancer therapies[J]. Recent Pat Anticancer Drug Discov, 2014, 9(2): 137152. |
[1] | Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325. |
[2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[3] | Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343. |
[4] | Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p, H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349. |
[5] | Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353. |
[6] | Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358. |
[7] | Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363. |
[8] | Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369. |
[9] | Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375. |
[10] | Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381. |
[11] | Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273. |
[12] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[13] | Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285. |
[14] | Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291. |
[15] | Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||